# A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

> **NCT02264574** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 229 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small-Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT02264574
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-06
- **Primary completion:** 2018-03-26
- **Final completion:** 2019-09-03
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2020-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264574, "A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02264574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*